In addition to teratocarcinoma, HML-2 expression is often observed in other cancers, including breast cancer [21,22,23,24,25,26] and melanoma [27,28], and during HIV-1 infection [29,30,31,32,33,34]. Here, CLEC10A is linked to teratocarcinoma.